Parameter | Group | n | Week-0 | Week-12 | Change from baseline |
---|---|---|---|---|---|
Total fat area (cm2) | Placebo | 14 | 301.7 ± 50.6 | 318.1 ± 50.4 | 16.3 ± 34.1 |
GH | 15 | 304.3 ± 41.8 | 299.7 ± 44.1 | −4.6 ± 20.5 | |
GH + Caf 25 | 15 | 297.9 ± 54.8 | 293.7 ± 61.5 | −4.2 ± 18.2 | |
GH + Caf 50 | 15 | 295.1 ± 53.7 | 286.7 ± 48.9 | −8.4 ± 21.9# | |
GH + Caf 75 | 15 | 310.8 ± 43.9 | 293.9 ± 45.5 | −17.0 ± 31.4## | |
Visceral fat area (cm2) | Placebo | 14 | 97.2 ± 53.1 | 102.3 ± 61.9 | 5.1 ± 25.9 |
GH | 15 | 97.6 ± 27.7 | 96.6 ± 27.5 | −1.1 ± 15.0 | |
GH + Caf 25 | 15 | 107.5 ± 42.3 | 103.6 ± 40.0 | −3.8 ± 14.5 | |
GH + Caf 50 | 15 | 108.1 ± 46.1 | 109.0 ± 46.6 | 0.9 ± 11.3 | |
GH + Caf 75 | 15 | 101.1 ± 28.9 | 96.5 ± 33.7 | −4.5 ± 16.1 | |
Subcutaneous fat area (cm2) | Placebo | 14 | 204.6 ± 59.5 | 215.8 ± 63.5* | 11.2 ± 18.3 |
GH | 15 | 206.6 ± 45.4 | 203.1 ± 44.2 | −3.5 ± 11.8 | |
GH + Caf 25 | 15 | 190.4 ± 59.0 | 190.1 ± 60.1 | −0.4 ± 14.3 | |
GH + Caf 50 | 15 | 187.0 ± 48.0 | 177.7 ± 44.0 | −9.3 ± 17.1## | |
GH + Caf 75 | 15 | 209.8 ± 45.4 | 197.3 ± 44.4* | −12.4 ± 18.7## |